Benserazide is a peripheral dopa-decarboxylase inhibitor used alongside levodopa for treating Parkinson’s disease. Its main function is to prevent levodopa breakdown outside the brain, increasing the amount that reaches the central nervous system. This enhances levodopa’s effect while reducing peripheral side effects such as nausea, vomiting, and cardiovascular issues. Benserazide does not cross the blood–brain barrier and has no direct effect on Parkinson’s symptoms when used alone. It is usually combined with levodopa in fixed-dose formulations.
BRAND NAMES
Benserazide is commonly available only in combination with levodopa for Parkinson’s disease. It is marketed under brand names such as Madopar, Prolopa, Benspar, Cenparkin, and Neodopasol in different countries. These combinations enhance levodopa’s effect while reducing peripheral side effects, and the exact brand names and formulations vary by region.
MECHANISM OF ACTION
Benserazide is a peripheral dopa‑decarboxylase inhibitor that prevents levodopa from being converted to dopamine outside the brain. This increases levodopa delivery to the central nervous system, enhancing its effect and reducing peripheral side effects.
PHARMACOKINETICS
Absorption
Benserazide is rapidly absorbed from the gastrointestinal tract when taken orally. However, it is largely confined to the periphery and does not cross the blood–brain barrier. Its absorption ensures effective inhibition of peripheral dopa‑decarboxylase, allowing more levodopa to reach the brain.
Distribution
Benserazide is widely distributed in peripheral tissues but does not cross the blood–brain barrier. As a result, its action is limited to the periphery, where it inhibits the conversion of levodopa to dopamine outside the central nervous system.
Metabolism
Benserazide is extensively metabolized in peripheral tissues, primarily by enzymatic pathways, into inactive metabolites. It undergoes rapid biotransformation, which limits its systemic persistence and confines its action to the periphery.
Excretion
Benserazide and its metabolites are primarily excreted via the kidneys in urine, with a small amount eliminated through feces.
PHARMACODYNAMICS
Benserazide enhances the effect of levodopa by inhibiting peripheral dopa-decarboxylase, thereby increasing the availability of levodopa in the brain. This leads to higher central dopamine levels, improving motor symptoms of Parkinson’s disease while reducing peripheral adverse effects such as nausea and cardiovascular disturbances. Benserazide itself has no direct central activity.
ADMINISTRATION
Benserazide is administered orally in combination with levodopa as fixed-dose formulations. It is usually taken in divided doses throughout the day, preferably before or with meals to improve tolerance. Dosage is individualized and gradually adjusted based on the patient’s response and tolerability.
DOSAGE AND STRENGTH
Benserazide is available only in combination with levodopa. Common fixed-dose strengths include levodopa 50 mg + benserazide 12.5 mg, 100 mg + 25 mg, and200 mg + 50 mg. Treatment is usually started at a low dose and gradually increased based on patient response and tolerance, with doses taken in divided administrations throughout the day.
FOOD INTERACTIONS
High-protein foods can reduce the absorption and effectiveness of levodopa with benserazide by competing for transport. Therefore, it is best taken before or between meals, or protein intake should be evenly distributed throughout the day to maintain its effect.
DRUG INTERACTIONS
Benserazide (with levodopa) may interact with non-selective MAO inhibitors (risk of hypertensive crisis), antipsychotics (reduce therapeutic effect), and antihypertensives (enhanced hypotension). Vitamin B6 (pyridoxine) can increase peripheral metabolism of levodopa, but this effect is minimized when combined with benserazide. Additionally, iron supplements may reduce levodopa absorption.
CONTRAINDICATIONS
Benserazide (with levodopa) is contraindicated in patients with hypersensitivity to the drug, narrow-angle glaucoma, severe psychosis, and concurrent use of non-selective MAO inhibitors. It should also be avoided in patients with severe cardiovascular, hepatic, renal, or endocrine disorders, and in pregnancy unless clearly necessary.
SIDE EFFECTS
Nausea
Vomiting
Loss of appetite
Dizziness
Orthostatic hypotension
sleep disturbances
Dyskinesia
Hallucinations
Mood changes
Darkening of urine or sweat
TOXICITY
Overdose of benserazide (with levodopa) can lead to severe nausea, vomiting, low blood pressure, cardiac arrhythmias, confusion, agitation, and dyskinesia. In extreme cases, respiratory depression, seizures, or comamay occur. Management is supportive, including gastric lavage, intravenous fluids, monitoring of vital signs, and symptomatic treatment.
